Please login to the form below
mantle cell lymphoma
This page shows the latest mantle cell lymphoma news and features for those working in and with pharma, biotech and healthcare.
FDA priority review granted for BeiGene’s Brukinsa for marginal zone lymphoma
BeiGene’s Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa has been granted a priority review by the US Food and Drug Administration (FDA) for pretreated marginal zone lymphoma (MZL). ... If approved, MZL will become Brukinsa’s second indication
Latest news
-
Kite and Oxford BioTherapeutics sign oncology research pact
relapsed or refractory B-cell lymphoma after two or more lines of systemic therapy. ... Yescarta was joined by Kite’s second CAR-T therapy Tecartus (brexucabtagene autoleucel) in July 2020, which is approved for the treatment of adults patients with
-
AZ’s BTK inhibitor Calquence fails in COVID-19 study
Calquence is approved to treat a number of blood cancers and is indicated for use in adults with previously treated mantle cell lymphoma (MCL) as well as adults with chronic lymphocytic ... leukaemia (CLL) or small lymphocytic lymphoma (SLL).
-
Merck strengthens oncology pipeline with $2.75bn VelosBio deal
resulted in objective clinical responses in 47% of patients with mantle cell lymphoma (MCL) and 80% of patients with diffuse large B-cell lymphoma (DLBCL). ... Pioneering work by VelosBio scientists has yielded VLS-101, which in early studies has
-
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma
X19 in relapsed or refractory mantle cell lymphoma. ... Despite recent advances, patients with relapsed/refractory mantle cell lymphoma currently face a significant lack of effective treatment options once their disease no longer responds to currently
-
EMA begins review of Kite’s CAR-T for mantle cell lymphoma
Kite is seeking approval for the CAR-T therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) – according to the company, if KTE-X19 is ... Relapse rates in mantle cell lymphoma remain overwhelmingly high and
Kite and Oxford BioTherapeutics sign oncology research pact
AZ’s BTK inhibitor Calquence fails in COVID-19 study
Merck strengthens oncology pipeline with $2.75bn VelosBio deal
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma
EMA begins review of Kite’s CAR-T for mantle cell lymphoma
More from news
Approximately 5 fully matching, plus 67 partially matching documents found.
Latest Intelligence
-
Encouraging signs in biomarker R&D
Similarly, high TMB is correlated with better response to immune checkpoint inhibitors, so is the presence of TIL or a T cell GEP. ... mantle cell lymphoma minimal as an example.
-
AstraZeneca: building a new ‘open innovation’ pharma company
AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.
Encouraging signs in biomarker R&D
AstraZeneca: building a new ‘open innovation’ pharma company
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Publications, Opthalmology, Medical Communicat...
-
Highly competitive salary
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Senior Medical Writer, Rare diseases, Medical Communications age...
-
Highly competitive salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Publications, Women’s health, Medical C...
-
Highly competitive salary
-
Planner
-
Salary TBC
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Publications, Opthalmology, Medical Com...
-
Highly competitive salary
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
-
Senior Account Manager
-
Salary TBC
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Court rules on AZ and EU’s COVID-19 vaccine dispute
- BMS and Eisai to collaborate in deal worth up to $3.1bn
- BMS’s oral AML therapy Onureg receives EU approval
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
- Breaking Down the Wall: Blockchain in Healthcare and Pharma
- Building Better Patient Advocates Through Authentic Partnerships
- Virgo Health makes two hires to leadership team
- Hanover Health appoints Aleksandra Lugović as an associate director
- GSK aims for £33bn in sales by 2031 as CEO Walmsley lays out ten-year strategy
- Biogen plans confirmatory trial as FDA documents show struggle over Aduhelm approval
- Biogen discontinues clinical development of anti-tau antibody for Alzheimer’s disease
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- BMS and Eisai to collaborate in deal worth up to $3.1bn
- Diversity and inclusion in clinical trials
- BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
PMHub
Mind+Matter
We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...
Latest intelligence
- Numbers, navigation, and narratives: digital storytelling in medical communications
- Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
- Is this common data mistake killing your digital patient recruitment?
- Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
- The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
- By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
